EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Pinar Horum, Katja Seipel iD, Inna Shaforostova, Martina Bertschinger iD, Ulrike Bacher iD, Thomas Pabst iD

Cancers · 16.03.2026 · 18 (6) · 963

DOI: 10.3390/cancers18060963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.03.2026. Verfasst von Pinar Horum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical outcomes for multiple myeloma are highly variable. Inherited genetic variants of immune regulatory genes can modulate disease susceptibility and clinical outcomes. The germline variant CTLA4 rs231775 polymorphism may alter T-cell function and affect clinical outcomes.

Methods

We conducted a retrospective single-center study including 156 consecutive myeloma patients who underwent first-line ASCT. The patients were stratified according to the CTLA4 rs231775 genotype and disease stage (ISS I–III).

Results

The CTLA4 rs231775 AA genotype was associated with inferior PFS in ISS I–II and superior PFS in ISS III. In the multivariate analysis, the CTLA4 rs231775 AA genotype emerged as a potential risk factor in ISS I-II and a potential protective factor in ISS III.

Conclusions

This germline CTLA4 polymorphism may serve as biomarker to refine post-transplant risk stratification and enable personalized treatment management.

Schlagwörter

Stichwörter der Autor:innen

autologous stem cell transplant (ASCT)cytotoxic T-lymphocyte-associated protein 4 (CTLA4)disease stage (ISS)multiple myeloma (MM)overall survival (OS)progression-free survival (PFS)single-nucleotide polymorphism (SNP)

Autor:innen und Institutionen

  • Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.

ORCID-Profile: Katja Seipel, Martina Bertschinger, Ulrike Bacher, Thomas Pabst

Zitieren

APA

Horum, P., Seipel, K., Shaforostova, I., Bertschinger, M., Bacher, U., & Pabst, T. (2026). Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation. Cancers, 18(6), 963. https://doi.org/10.3390/cancers18060963

Vancouver

Horum P, Seipel K, Shaforostova I, Bertschinger M, Bacher U, Pabst T. Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation. Cancers. 2026;18(6):963. doi:10.3390/cancers18060963

BibTeX
@article{Horum2026,
  author = {Horum, Pinar and Seipel, Katja and Shaforostova, Inna and Bertschinger, Martina and Bacher, Ulrike and Pabst, Thomas},
  title = {Disease Stage-Dependent Clinical Impact of CTLA4 Polymorphism in Multiple Myeloma Treated with Autologous Stem Cell Transplantation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {963},
  doi = {10.3390/cancers18060963}
}
Kostenlos starten →